PMID- 2419811
OWN - NLM
STAT- MEDLINE
DCOM- 19860331
LR  - 20180216
IS  - 0378-584X (Print)
IS  - 0378-584X (Linking)
VI  - 8
IP  - 4
DP  - 1985 Aug
TI  - [Therapy with inhibitors of polyamine biosynthesis in refractory prostatic 
      carcinoma. An experimental and clinical study].
PG  - 196-200
AB  - Transplantable prostate adenocarcinoma were treated with polyamine biosynthetic 
      inhibitors. alpha-difluoromethylornithine (alpha-DFMO), an inhibitor of ornithine 
      decarboxylase and by s-methylglyoxal-bisguanylhydrazone (MGBG), an inhibitor of 
      s-adenosylmethionine decarboxylase. The therapeutic regimen of 0.8-1.11 g/kg DFMO 
      reduced the tumor growth by 40% whilst the combination with 10.5 mg/kg MGBG 
      completely destroyed the prostate adenocarcinomas in the tumor-bearing animals. 
      The polyamine content of spermidine and spermine in the cancerous tissues is 
      significantly lower whereas the putrescine levels remain unchanged. The MGBG 
      therapy distinctly stimulates the activity of ornithine decarboxylase and 
      increases the putrescine concentration up to toxic levels. The application of 
      alpha-DFMO prevented the toxic accumulation of putrescine and allowed higher 
      doses of MGBG. Clinical trials with polyamine antimetabolites appeared useful due 
      to pathological polyamine excretion of patients with metastatic prostate cancer. 
      The therapy with 0.2-0.3 g/kg DFMO in patients with hormone-resistent prostate 
      cancer and metastasis displayed a moderate anti-tumor activity following 2 months 
      additional treatment. High levels of side effects, however, were registered and 
      were similar to those of other cytotoxic compounds. A combined therapy with 
      DFMO/MGBG in a patient with metastatic anaplastic prostate cancer did not improve 
      the survival rate but showed regressive effects of the histological pattern.
FAU - Dunzendorfer, U
AU  - Dunzendorfer U
FAU - Knoner, M
AU  - Knoner M
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Therapie mit Inhibitoren der Polyaminbiosynthese beim refraktaren 
      Prostatakarzinom. Eine experimentelle und klinische Studie.
PL  - Switzerland
TA  - Onkologie
JT  - Onkologie
JID - 7808556
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Estrogens)
RN  - 0 (Ornithine Decarboxylase Inhibitors)
RN  - 2FZ7Y3VOQX (Spermine)
RN  - E524N2IXA3 (Ornithine)
RN  - EC 4.1.1.- (Carboxy-Lyases)
RN  - EC 4.1.1.50 (Adenosylmethionine Decarboxylase)
RN  - OD5Q0L447W (Mitoguazone)
RN  - U87FK77H25 (Spermidine)
RN  - V10TVZ52E4 (Putrescine)
RN  - ZQN1G5V6SR (Eflornithine)
SB  - IM
MH  - Adenocarcinoma/analysis/*drug therapy/urine
MH  - Adenosylmethionine Decarboxylase/*antagonists & inhibitors
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carboxy-Lyases/*antagonists & inhibitors
MH  - Carcinoma/*drug therapy
MH  - Eflornithine
MH  - Estrogens/therapeutic use
MH  - Humans
MH  - Male
MH  - Mitoguazone/adverse effects/*therapeutic use
MH  - Neoplasm Metastasis
MH  - Ornithine/adverse effects/*analogs & derivatives/therapeutic use
MH  - *Ornithine Decarboxylase Inhibitors
MH  - Prostatic Hyperplasia/urine
MH  - Prostatic Neoplasms/analysis/*drug therapy/urine
MH  - Prostatitis/urine
MH  - Putrescine/analysis/urine
MH  - Rats
MH  - Spermidine/analysis/urine
MH  - Spermine/analysis/urine
EDAT- 1985/08/01 00:00
MHDA- 1985/08/01 00:01
CRDT- 1985/08/01 00:00
PHST- 1985/08/01 00:00 [pubmed]
PHST- 1985/08/01 00:01 [medline]
PHST- 1985/08/01 00:00 [entrez]
AID - 10.1159/000215710 [doi]
PST - ppublish
SO  - Onkologie. 1985 Aug;8(4):196-200. doi: 10.1159/000215710.